Page 1

ABLIVA We continue to build the foundations to deliver on our goal of becoming the leader in the development of therapeutics for patients suffering from primary mitochondrial diseases . Ellen Donnelly , CEO Interim Report January - September 2021 2 Delivering mitochondrial health